Viking Therapeutics to Present at Key Investor Conferences in June

Event summary

  • Viking Therapeutics will present at the William Blair Growth Stock Conference on June 2 and the Jefferies Global Healthcare Conference on June 4.
  • The company will deliver a corporate presentation, participate in a fireside chat, and hold investor meetings at both events.
  • Viking's Phase 3 obesity trials (VANQUISH-1 and VANQUISH-2) for VK2735 are ongoing, with positive Phase 1 and Phase 2 data.
  • VK2809 achieved primary and secondary endpoints in a Phase 2b NASH trial and showed significant LDL-C and liver fat reductions in a Phase 2a NAFLD trial.

The big picture

Viking Therapeutics is leveraging investor conferences to showcase its pipeline, particularly in obesity and metabolic disorders, amid a competitive landscape of GLP-1 and GIP receptor agonists. The company's focus on dual mechanisms and oral formulations positions it to challenge established players if clinical and regulatory milestones are met. The upcoming presentations will be critical in gauging investor appetite for its high-risk, high-reward development strategy.

What we're watching

Clinical Progress
How the Phase 3 data for VK2735 will impact Viking's obesity treatment strategy and competitive positioning.
Investor Sentiment
Whether the upcoming presentations will shift market perception of Viking's pipeline and execution capabilities.
Regulatory Pathways
The pace at which VK2809 advances through late-stage trials for NASH and NAFLD indications.